Report on the Issue and Use of Immunoglobulin

Immunoglobulin (Ig) products, derived from pooled human plasma, are a precious and high-cost resource. Strengthening Ig governance is a priority for the National Blood Authority (NBA), and several measures are being developed and implemented to ensure the sustainability of these products into the future.

Immunoglobulin products analysed in these reports include intravenous immunoglobulin (IVIg), subcutaneous immunoglobulin (SCIg), and normal human immunoglobulin (NHIg). Aggregated data for IVIg and SCIg are referred to as Ig unless specifically stated. Normal human Ig is reported separately. Immunoglobulin products are used to treat a broad range of conditions, with applications in replacement and immune modulation therapy. These reports provide an analysis of national data on national Ig supply in Australia.